Séverine Vermeire

Research interests

Publications

• Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00581-5

• Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?

  EBioMedicine · 2021 · https://doi.org/10.1016/j.ebiom.2021.103293

• Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00666-8

• JAK–STAT pathway targeting for the treatment of inflammatory bowel disease

  Nature Reviews Gastroenterology & Hepatology · 2020 · 10.1038/s41575-020-0273-0

• The intestinal barrier: a fundamental role in health and disease

  Expert Review of Gastroenterology & Hepatology · 2017 · 10.1080/17474124.2017.1343143

• A microbial signature for Crohn's disease

  Gut · 2017 · https://doi.org/10.1136/gutjnl-2016-313235

• Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1606910

• Quantitative microbiome profiling links gut community variation to microbial load

  Nature · 2017 · https://doi.org/10.1038/nature24460

• Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1602773

• Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

  Gastroenterology · 2015 · 10.1053/j.gastro.2015.02.031

• Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study

  The Lancet · 2015 · 10.1016/s0140-6736(15)00465-1

• A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis

  Gut · 2013 · https://doi.org/10.1136/gutjnl-2013-304833

• Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

  Journal of Crohn s and Colitis · 2012 · 10.1016/j.crohns.2012.09.002

• Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

  Inflammatory Bowel Diseases · 2012 · 10.1002/ibd.22917

• Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis

  Journal of Crohn s and Colitis · 2012 · 10.1016/j.crohns.2012.09.003

• Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives

  Gut · 2011 · 10.1136/gut.2010.223263

• Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

  Nature Genetics · 2010 · https://doi.org/10.1038/ng.717

• Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

  Gastroenterology · 2009 · 10.1053/j.gastro.2009.09.056

• The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

  Journal of Crohn s and Colitis · 2009 · 10.1016/j.crohns.2009.09.009

• Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease

  Inflammatory Bowel Diseases · 2009 · 10.1002/ibd.20927

• Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

  Nature Genetics · 2008 · https://doi.org/10.1038/ng.175

• Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

  The Lancet · 2008 · 10.1016/s0140-6736(08)60304-9

• Laboratory markers in IBD: useful, magic, or unnecessary toys?

  Gut · 2006 · 10.1136/gut.2005.069476

• Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease

  New England Journal of Medicine · 2005 · 10.1056/nejmoa051586

• Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

  Canadian Journal of Gastroenterology · 2005 · https://doi.org/10.1155/2005/269076

• VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death

  Nature Genetics · 2003 · 10.1038/ng1211

• Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

  New England Journal of Medicine · 2003 · https://doi.org/10.1056/nejmoa020888

Current projects

No projects listed.